Familial multiple lipomatosis

Summary

Familial multiple lipomatosis (MONDO:0007909) is a disease and 1 clinical trial. A subtype of integumentary system benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Phenotypes (HPO): 8
• Clinical trials: 1

Clinical features

Signs & symptoms

Clinical features (HPO)

8 HPO clinical features (Orphanet curated; top 8 by frequency):

HPO ID	Term	Frequency
HP:0001012	Multiple lipomas	Very frequent (80-99%)
HP:0001031	Subcutaneous lipoma	Very frequent (80-99%)
HP:0001513	Obesity	Occasional (5-29%)
HP:0006773	Cutaneous angiolipomas	Occasional (5-29%)
HP:0009830	Peripheral neuropathy	Occasional (5-29%)
HP:0025502	Overweight	Occasional (5-29%)
HP:0007596	Painful subcutaneous lipomas	Very rare (<1-4%)
HP:0007618	Subcutaneous calcification	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	familial multiple lipomatosis
Mondo ID	MONDO:0007909
MeSH	D000071070
OMIM	151900
Orphanet	199276
DOID	DOID:0070518
SNOMED CT	766888002
UMLS	C1275273
MedGen	698553
GARD	0012925
Is cancer (heuristic)	no

Disease family

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system benign neoplasm › familial multiple lipomatosis

Related subtypes (7): Bartholin gland benign neoplasm, hemangioma of subcutaneous tissue, adiposis dolorosa, multiple symmetric lipomatosis, intraductal breast papilloma, adenoma of nipple, benign neoplasm of skin

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02838277	Not specified	UNKNOWN	Insight Into Subcutaneous Adipose Tissue Disorders